Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients

NCT03096093 is registered in ClinicalTrials.gov with Cancer Vaccines Limited as lead sponsor.

NCT NCT03096093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03096093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Lead sponsor
Cancer Vaccines Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 25, 2017
Completion date
July 31, 2027
Enrollment
34 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasms